^
    14d
    PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer. (PubMed, Mol Cancer Ther)
    Additionally, SCR-6920 improves the efficacy of clinical first-line ovarian cancer therapies (paclitaxel, docetaxel, doxorubicin, and olaparib). This study identifies a promising PRMT5 inhibitor with synergistic activity with bevacizumab and reveals its regulation of HIF-1α signaling, highlighting the therapeutic potential of PRMT5 inhibition in combination regimens for ovarian cancer.
    Journal • PARP Biomarker
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • paclitaxel • docetaxel • doxorubicin hydrochloride • SIM0272
    14d
    PRMT5 inhibition by SCR-6920 downregulates HIF-1α and exhibits synergistic antitumor activity with bevacizumab in ovarian cancer. (PubMed, Mol Cancer Ther)
    Additionally, SCR-6920 improves the efficacy of clinical first-line ovarian cancer therapies (paclitaxel, docetaxel, doxorubicin, and olaparib). This study identifies a promising PRMT5 inhibitor with synergistic activity with bevacizumab, and reveals its regulation of HIF-1α signaling, highlighting the therapeutic potential of PRMT5 inhibition in combination regimens for ovarian cancer.
    Journal • PARP Biomarker
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • paclitaxel • docetaxel • doxorubicin hydrochloride • SIM0272
    almost3years
    A phase I study of safety, pharmacokinetics, and pharmacodynamics of SCR-6920, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced malignant tumors (ESMO 2023)
    Plasma symmetric dimethyl arginine (SDMA), the enzymatic product of PRMT5 was significantly reduced (inhibitory rate: 52.8%∼77.4%) at steady state. Conclusions SCR-6920 had a manageable safety profile and further assessments are ongoing to determine the RP2Ds.
    Clinical • P1 data • PK/PD data • Metastases
    |
    PRMT5 (Protein Arginine Methyltransferase 5)
    |
    SIM0272
    over3years
    A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=122, Recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd.
    New P1 trial
    |
    PRMT5 (Protein Arginine Methyltransferase 5)
    |
    SIM0272